GO:0106140 P-TEFb complex binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106140 (P-TEFb complex binding) is a molecular function defined as binding to a P-TEFb complex.
• P-TEFb is a cyclin-dependent kinase complex composed of CDK9 and a cyclin partner (CCNT1 or CCNT2) that controls RNA polymerase II transcription elongation.
• P-TEFb complex binding is a key step in recruiting and regulating the positive transcription elongation factor b, which phosphorylates the RNA polymerase II C-terminal domain and negative elongation factors.
• Proteins that bind P-TEFb include BRD4, TAT, HEXIM1, and components of the 7SK snRNP, which modulate its activity in transcription and disease.
• Dysregulation of P-TEFb complex binding is implicated in cancers such as chronic myeloid leukemia and in other diseases, making it a therapeutic target.
• CRISPR-based knockout, knock-in, and overexpression models are essential to study the function of P-TEFb complex binding proteins in cells.
Description
GO:0106140, P-TEFb complex binding, is a molecular function term in the Gene Ontology that describes the binding to the positive transcription elongation factor b (P-TEFb) complex. P-TEFb is a master regulator of transcription elongation by RNA polymerase II, and its recruitment to target genes is critical for efficient transcription. Proteins that bind P-TEFb can either activate or inhibit its kinase activity, thereby fine-tuning gene expression programs. Understanding P-TEFb complex binding is therefore central to deciphering how transcription elongation is controlled in normal and diseased cells. This term is particularly important because P-TEFb is a hub for multiple regulatory inputs, including the 7SK small nuclear ribonucleoprotein (snRNP) and bromodomain-containing protein 4 (BRD4). The binding of these factors to P-TEFb determines whether the complex is active or sequestered, impacting processes such as cell cycle progression, differentiation, and stress responses. Moreover, pharmacological targeting of P-TEFb complex interactions is being explored as a therapeutic strategy in cancer and other diseases. Researchers studying P-TEFb complex binding need reliable models to dissect the molecular interactions and functional consequences. CRISPR-based gene editing enables precise manipulation of genes encoding P-TEFb subunits and its binding partners, facilitating mechanistic studies and drug discovery. This article provides a comprehensive overview of GO:0106140, covering its definition, biological significance, key genes, research methods, and how EDITGENE's services can accelerate your research.
P-TEFb complex binding At A Glance
| GO ID | GO:0106140 |
|---|---|
| GO term | P-TEFb complex binding |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Binding to a P-TEFb complex. |
| Major function | Mediates interaction with the P-TEFb complex to regulate transcription elongation. |
| Related complex | P-TEFb (CDK9-CCNT1/CCNT2) |
| Key regulators | BRD4, HEXIM1, 7SK snRNP, TAT |
| Disease relevance | Cancer, leukemia, HIV, cardiac hypertrophy |
What Is GO:0106140?
According to the Gene Ontology, GO:0106140 (P-TEFb complex binding) is defined as the binding to a P-TEFb complex. In other words, it is a molecular function performed by a protein or a complex that physically interacts with the P-TEFb complex, which consists of CDK9 and a cyclin T subunit (CCNT1 or CCNT2). This binding event can occur through various domains, such as bromodomains or other interaction motifs, and it serves to recruit, stabilize, or modulate the activity of P-TEFb in transcription regulation.
Why Is P-TEFb complex binding Important in Cell Biology?
P-TEFb complex binding is a critical molecular function because it controls the recruitment and activity of P-TEFb, the master regulator of RNA polymerase II transcription elongation. This function is essential for proper gene expression, and its dysregulation is linked to a wide range of diseases, including cancers, viral infections, and cardiovascular disorders. Understanding how proteins bind to P-TEFb provides insights into fundamental transcription mechanisms and offers opportunities for therapeutic intervention.
• Regulates transcription elongation by RNA polymerase II, a key step in gene expression.
• Controls cell growth, proliferation, and differentiation through P-TEFb-dependent genes.
• Implicated in cancer, including chronic myeloid leukemia and other malignancies.
• Plays a role in HIV transcription and latency via the viral protein Tat.
• Involved in cardiac hypertrophy and stress responses.
• Target for small-molecule inhibitors in cancer therapy.
• Essential for understanding the mechanism of action of BRD4 inhibitors.
• Provides a model for studying phase separation in transcription regulation.
• Key to interpreting CRISPR screens targeting transcription elongation factors.
• Facilitates the development of precision medicine approaches targeting P-TEFb interactions.
Molecular Mechanism of P-TEFb complex binding
Recognition and Binding to P-TEFb
In simple terms: Proteins that bind P-TEFb recognize and attach to the complex, often through specific domains.
The binding of proteins to the P-TEFb complex is mediated by specific interaction domains. For example, BRD4 binds to P-TEFb through its bromodomain and extraterminal (BET) domain, which recognizes acetylated histones and also interacts with P-TEFb. The HIV Tat protein binds to the cyclin T1 subunit of P-TEFb via its cysteine-rich region, recruiting P-TEFb to the viral promoter. These interactions are highly specific and are regulated by cellular signals and post-translational modifications.
Regulation by the 7SK snRNP
In simple terms: The 7SK snRNP complex can bind and hold P-TEFb in an inactive state.
The 7SK small nuclear ribonucleoprotein (snRNP) complex, containing HEXIM1 and the 7SK RNA, binds to P-TEFb and sequesters it in an inactive form. This binding is reversible and is controlled by signals that release P-TEFb for transcription. The interaction between HEXIM1 and P-TEFb is a key regulatory node for P-TEFb complex binding.
Phosphorylation and Activation
In simple terms: Once bound, P-TEFb phosphorylates targets to activate transcription.
Upon binding to its partners, P-TEFb phosphorylates the C-terminal domain (CTD) of RNA polymerase II at serine 2 and the negative elongation factors DSIF and NELF, leading to productive transcription elongation. This kinase activity is dependent on the binding of regulatory proteins that recruit P-TEFb to specific genomic loci.
Phase Separation and Compartmentalization
In simple terms: P-TEFb and its binding partners can form liquid droplets to concentrate transcription machinery.
Recent studies have shown that P-TEFb complex binding can involve phase separation. For instance, the transcriptional coactivator TAZ undergoes phase separation to compartmentalize P-TEFb and other transcription factors, enhancing gene expression. This mechanism provides a new layer of regulation for P-TEFb complex binding and transcription elongation.
Therapeutic Targeting of P-TEFb Interactions
In simple terms: Drugs can disrupt P-TEFb binding to treat diseases like cancer.
Pharmacological inhibitors that disrupt P-TEFb complex binding, such as CDK9 inhibitors and BET inhibitors, are being developed for cancer therapy. These agents block the interaction between P-TEFb and its partners, leading to transcription inhibition and cell death in cancer cells. Understanding the structural basis of these interactions is crucial for rational drug design.
Key Genes Involved in GO:0106140 P-TEFb complex binding
The following genes encode proteins that are directly involved in P-TEFb complex binding or are components of the P-TEFb complex itself.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDK9 | Catalytic subunit of P-TEFb; phosphorylates RNA Pol II CTD | Core kinase; target of inhibitors; essential for transcription elongation |
| CCNT1 | Regulatory cyclin T1 subunit of P-TEFb | Binds Tat and HEXIM1; determines substrate specificity |
| CCNT2 | Cyclin T2 subunit of P-TEFb | Alternative cyclin partner; regulates P-TEFb activity |
| BRD4 | Binds P-TEFb via BET domain; recruits to chromatin | Master transcription elongation factor; target of BET inhibitors |
| HEXIM1 | Binds and inhibits P-TEFb in 7SK snRNP | Key regulator of P-TEFb sequestration |
| TAZ | Phase separation component; binds P-TEFb | Links phase separation to transcription regulation |
| TAT | HIV protein that binds P-TEFb | Recruits P-TEFb to viral promoter; role in HIV latency |
| PP2A | Phosphatase that regulates CDK9 phosphorylation | Fine-tunes P-TEFb activity; part of Integrator complex |
| INTEGRATOR | Complex that interacts with P-TEFb | Regulates transcription termination and pause release |
| 7SK RNA | Non-coding RNA in 7SK snRNP | Scaffolds HEXIM1-P-TEFb interaction |
| LARP7 | Component of 7SK snRNP | Stabilizes 7SK RNA and regulates P-TEFb |
| MEPCE | Methyltransferase that modifies 7SK RNA | Regulates 7SK snRNP assembly and P-TEFb binding |
| AFF4 | Component of SEC (super elongation complex) | Binds P-TEFb and regulates elongation |
| ELL2 | Component of SEC | Enhances P-TEFb activity |
| ENL | Component of SEC | Links P-TEFb to chromatin |
| AF9 | Component of SEC | Regulates P-TEFb recruitment |
| CDK9 inhibitors | Small molecules targeting CDK9 | Therapeutic tools for cancer |
| BET inhibitors | Small molecules targeting BRD4 | Disrupt P-TEFb binding to chromatin |
How Is P-TEFb complex binding Regulated?
P-TEFb complex binding is regulated at multiple levels. The 7SK snRNP dynamically sequesters P-TEFb in an inactive state, and signals such as stress or transcriptional activation can release P-TEFb. Post-translational modifications, including phosphorylation of CDK9 by PP2A and other kinases, modulate the stability and activity of the complex. Additionally, phase separation of proteins like TAZ can concentrate P-TEFb and its binding partners, influencing transcription. BET proteins such as BRD4 compete with 7SK snRNP for P-TEFb binding, thereby regulating the active pool of P-TEFb.
P-TEFb complex binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDK9 | Chronic myeloid leukemia; cancer | Knockout or point-mutation in CML cell lines; xenograft models |
| BRD4 | Multiple cancers; BET inhibitor response | Knockout or overexpression in cancer cell lines; patient-derived xenografts |
| HEXIM1 | Cardiac hypertrophy; cancer | Knockout mouse models; cardiomyocyte cell lines |
| TAT | HIV infection and latency | Knock-in of Tat in HIV reporter cell lines; latency models |
| PP2A | Cancer; transcription regulation | Knockout or point mutation in cancer cell lines; CRISPR screens |
P-TEFb complex binding in cancer
Dysregulation of P-TEFb complex binding is a hallmark of many cancers. In chronic myeloid leukemia (CML), pharmacological targeting of the P-TEFb complex has been proposed as a therapeutic strategy. BET inhibitors, which disrupt BRD4-P-TEFb binding, show efficacy in various cancers. The PP2A-Integrator-CDK9 axis is also a target in cancer, as its perturbation affects transcription elongation.
P-TEFb complex binding in viral infections
The HIV Tat protein binds to P-TEFb and recruits it to the viral promoter, a critical step for viral transcription and latency. Understanding this interaction has informed strategies to reactivate latent HIV reservoirs.
P-TEFb complex binding in cardiac disease
P-TEFb is involved in cardiac hypertrophy, where its interaction with regulatory proteins controls pathological gene expression. Targeting P-TEFb complex binding may offer therapeutic benefits in heart disease.
From P-TEFb complex binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CDK9 kinase activity require P-TEFb complex binding? | CDK9 knockout with rescue by wild-type or binding-deficient mutant |
| How does BRD4 binding to P-TEFb affect transcription? | BRD4 knockout or point mutation in bromodomain; RNA-seq |
| What is the role of HEXIM1 in P-TEFb sequestration? | HEXIM1 knockout or knock-in of binding-deficient mutant; co-IP |
| Can phase separation of TAZ regulate P-TEFb binding? | TAZ knockout or overexpression of phase-separation-deficient mutant; imaging |
| How does PP2A regulate CDK9 phosphorylation? | PP2A knockout or point mutation; phospho-proteomics |
| What is the impact of Tat binding to P-TEFb on HIV latency? | Tat knock-in or knockout in HIV latency models; reporter assays |
How to Study the P-TEFb complex binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP/MS | Protein-protein interactions with P-TEFb | Identify novel binding partners |
| ChIP-seq | Genomic binding sites of P-TEFb and partners | Map transcription elongation complexes |
| CRISPR knockout screens | Gene essentiality and resistance | Discover regulators of P-TEFb binding |
| RNA-seq | Transcriptional changes upon perturbation | Assess impact of P-TEFb binding on gene expression |
| Phospho-proteomics | Phosphorylation of CDK9 and substrates | Study regulation by PP2A |
| FRAP | Dynamics of phase-separated condensates | Measure P-TEFb condensate properties |
| Proximity labeling (TurboCas) | Locus-specific interactome | Isolate proteins at P-TEFb-bound loci |
| BET inhibitor assays | Disruption of BRD4-P-TEFb binding | Drug screening |
Co-immunoprecipitation and Mass Spectrometry
Co-immunoprecipitation (co-IP) followed by mass spectrometry is a standard method to identify proteins that bind to P-TEFb. This approach can reveal novel P-TEFb complex binding partners and their stoichiometry. TurboCas, a proximity labeling method, enables locus-specific labeling and isolation of associated protein interactomes, including P-TEFb components.
Chromatin Immunoprecipitation (ChIP)
ChIP assays using antibodies against P-TEFb subunits or its binding partners can determine their genomic localization and co-occupancy at target genes. ChIP-seq provides genome-wide maps of P-TEFb complex binding sites.
CRISPR Screens and Functional Genomics
CRISPR knockout screens targeting genes involved in P-TEFb complex binding can identify essential regulators of transcription elongation and drug resistance. These screens are powerful for discovering novel components and therapeutic targets.
Live-Cell Imaging and Phase Separation Assays
Fluorescence microscopy and live-cell imaging can visualize the formation of P-TEFb-containing condensates and their dynamics. FRAP and droplet assays are used to study phase separation of P-TEFb and its partners.
How CRISPR Can Be Used to Study GO:0106140 P-TEFb complex binding
Knockout
CRISPR knockout of genes encoding P-TEFb subunits (CDK9, CCNT1) or binding partners (BRD4, HEXIM1) can reveal their essential roles in transcription and cell viability. Knockout cell lines are valuable for studying the loss of P-TEFb complex binding and its downstream effects.
Point Mutation
Introducing point mutations in the interaction domains of P-TEFb or its partners (e.g., bromodomain of BRD4, cysteine-rich region of Tat) allows precise dissection of binding interfaces without affecting protein expression. These models are crucial for understanding specificity and affinity.
Knock-in
Knock-in of tagged versions of P-TEFb subunits or binding partners (e.g., GFP, HA, or proximity labeling tags) enables endogenous localization and interactome studies. Tagged knock-in models facilitate live-cell imaging and proteomics.
Overexpression
Overexpression of P-TEFb components or binding partners can mimic disease states or enhance transcription elongation. These models are useful for gain-of-function studies and drug testing.
How EDITGENE Supports P-TEFb complex binding Research
Researchers studying P-TEFb complex binding-related genes often need to determine whether a candidate gene is causally involved in transcription regulation, disease progression, or drug response. EDITGENE provides comprehensive CRISPR gene editing services to create precisely tailored cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for P-TEFb complex binding research.
Frequently Asked Questions About P-TEFb complex binding
What is GO:0106140?
GO:0106140 is the Gene Ontology molecular function term for P-TEFb complex binding, defined as binding to a P-TEFb complex.
What is P-TEFb?
P-TEFb is a cyclin-dependent kinase complex composed of CDK9 and a cyclin T subunit (CCNT1 or CCNT2) that regulates transcription elongation by RNA polymerase II.
What genes are involved in P-TEFb complex binding?
Key genes include CDK9, CCNT1, CCNT2, BRD4, HEXIM1, TAZ, and TAT, among others.
How does P-TEFb complex binding regulate transcription?
Binding of proteins to P-TEFb can recruit it to chromatin, activate its kinase activity, or sequester it in an inactive state, thereby controlling transcription elongation.
What diseases are associated with P-TEFb complex binding?
Dysregulation is linked to cancers such as chronic myeloid leukemia, HIV infection, and cardiac hypertrophy.
What methods are used to study P-TEFb complex binding?
Common methods include co-immunoprecipitation, mass spectrometry, ChIP-seq, CRISPR screens, and live-cell imaging.
Can CRISPR be used to study P-TEFb complex binding?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect the function of P-TEFb and its binding partners.
What is the role of BRD4 in P-TEFb complex binding?
BRD4 binds to P-TEFb via its BET domain and recruits it to acetylated chromatin, acting as a master transcription elongation factor.
How is P-TEFb complex binding regulated?
It is regulated by the 7SK snRNP, post-translational modifications, and phase separation, which control the active pool of P-TEFb.
What are the therapeutic implications of targeting P-TEFb complex binding?
Inhibitors that disrupt P-TEFb interactions, such as CDK9 and BET inhibitors, are being developed for cancer therapy.
Conclusion
GO:0106140 (P-TEFb complex binding) is a fundamental molecular function that governs transcription elongation by RNA polymerase II. Its dysregulation contributes to cancer, viral infections, and cardiovascular diseases, making it a prime target for therapeutic intervention. Advances in CRISPR gene editing and functional genomics are enabling precise dissection of the interactions and regulatory mechanisms involved. EDITGENE's comprehensive services support researchers in creating tailored cell models to study P-TEFb complex binding and accelerate drug discovery.
References
- 1. Fujinaga K et al.. 2023. P-TEFb: The master regulator of transcription elongation.. Mol Cell 83(3):393-403 PMID: 36599353
- 2. Brès V et al.. 2008. The multi-tasking P-TEFb complex.. Curr Opin Cell Biol 20(3):334-40 PMID: 18513937
- 3. Schier AC et al.. 2020. Structure and mechanism of the RNA polymerase II transcription machinery.. Genes Dev 34(7-8):465-488 PMID: 32238450
- 4. Cenik BK et al.. 2024. TurboCas: A method for locus-specific labeling of genomic regions and isolating their associated protein interactome.. Mol Cell 84(24):4929-4944.e8 PMID: 39706164
- 5. Qing Y et al.. 2021. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.. Cell Commun Signal 19(1):83 PMID: 34372855
- 6. Lu Y et al.. 2020. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression.. Nat Cell Biol 22(4):453-464 PMID: 32203417
- 7. Vervoort SJ et al.. 2021. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.. Cell 184(12):3143-3162.e32 PMID: 34004147
- 8. Winter GE et al.. 2017. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.. Mol Cell 67(1):5-18.e19 PMID: 28673542
